CPP is a condition involving the premature onset of puberty in girls younger than 8 years old and boys younger than 9 years old.
Triptodur is a hormone agonist designed to regulate hormone levels and delay puberty until the child is of an appropriate age. The drug is administered through intramuscular injection once every six months.
Debiopharm International — a unit of Switzerland-based Debiopharm Group — developed Triptodur, and Atlanta-based Arbor Pharmaceuticals acquired the U.S. rights to the drug in 2015. Triptodur will hit the U.S. market in the fourth quarter of 2017.
More articles on supply chain:
Precision benchmarking a panacea for purchased services savings
Vertex Pharma makes 1st price hike on cystic fibrosis drug
Novo Nordisk recalls insulin pen cartridge holders
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
